BioSpace News Archive

Panbela Therapeutics, Inc announces a poster presentation highlighting the results for CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes at the Immunology of Diabetes Society (IDS) meeting, which was held May 23-27, 2023.

Rallybio Corporation today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9 at 9:00AM ET in New York, NY.

Equillium, Inc. today announced that it will present at the Jefferies Global Healthcare Conference and the LD Micro Invitational Conference.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of UPLIZNA, which offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of UPLIZNA in reducing these biomarker levels, potentially reducing the frequency and severity of these attacks.

OcuTerra Therapeutics, Inc. today announced the appointment of Bill Steinkrauss as Chief Financial Officer.

Recursion, a clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conferences:

Pharming Group N.V. announces that it has entered into a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Oxurion NV, a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that the company will participate in three conferences in June:

invoX Pharma Limited announced that it has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.

Croma-Pharma announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom, and Ireland.